> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
> See specialized channels

  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter

BioGenes Launches 2-D DIGE Western Blot for HCP Detection and Quantification

| Print |
Wednesday, 18 June 2014 16:15 (UTC + 2)

BioGenes logo

Berlin, Germany, June 18, 2014 / B3C newswire / - BioGenes GmbH, a leader in host cell protein (HCP) assay development for biomanufacturing processes, announce the availability of a 2-D DIGE Western Blot service for highly accurate determination and electronic quantification of HCP coverage.

2-D DIGE Western Blot is a DIGE based fluorescent two-dimensional gel electrophoresis combined with a Western Blot that detects whole protein and HCP antibody signals on the same membrane. It allows the protein spots to be aligned perfectly with immuno-detected spots, thus eliminating any gel-to-membrane variations. 2-D DIGE Western Blot uses two CyDye fluorescent dyes for labelling of total protein and HCP antibodies which enable signal detection at different wavelengths. CyDye fluorescence labelling is very sensitive and produces sharp and clear spots allowing an accurate and fully electronic analysis.

HCPs comprise the majority of protein contaminants derived from the manufacturing of therapeutic proteins and vaccines. HCPs are often immunogenic, can alter the therapeutic efficacy of a therapeutic drug substance and may affect patient safety. Therefore, the detection and quantification of HCPs is a major precondition for clinical trials of therapeutic proteins in human beings.

ELISA is a widely used technique to measure the residual HCPs and assess product purity. The current technique for estimating coverage of the HCP antibodies to the total HCPs present in a cell line is the comparison of a Coomassie Blue stained 2-D gel electrophoresis with an immunologically stained 2-D Western Blot. However, this technique may produce errors in pattern alignment between gel and membrane, is less sensitive than fluorescence and the results cannot be evaluated electronically.

About BioGenes GmbH
BioGenes GmbH specializes in highly sophisticated and customized antibody and immunoassay development and is an experienced and reliable partner for process development improvements in all areas of quality control, diagnostics and drug discovery. BioGenes is certified to meet the international requirements and regularities of quality assurance and animal welfare. The Company maintains long-term relationships with research institutes, universities and biotech and pharmaceutical companies, including eight of the ten largest pharmaceutical companies in the world. The company has been evaluated by a leading global accounting and auditing firm to be one of the leading companies in HCP assay development.


Dagmar Schwertner-Knoll
Marketing/Sales Director
BioGenes GmbH
This e-mail address is being protected from spambots. You need JavaScript enabled to view it